KEYNOTE-859: Keytruda (pembrolizumab) plus chemotherapy for the first line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma

Supporting documentation

Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.